We have translated from our cutting-edge proteomics datasets into two types of "targets"
Biomarker: we have validated various biomarkers for multiple mental diseases, aiming for innovative molecular diagnostics products in a field with none available.
Drug target: our drug targets originate from patients' proteomic insights with a focus in oncology. Multiple lead molecules based on our First-in-class Tumor Associated Antigen (TAA) identification capacity have been identified and are under further development.
Our Research Strategy is From Bed to Bed